Institute of Bioanalytical Chemistry Centre for Biotechnology and Biomedicine (BBZ) Faculty of Chemistry and Mineralogy Leipzig University Leipzig Germany
Auto-generated profile, based on publicly available information
Sebastian Braun
Institute of Bioanalytical Chemistry Centre for Biotechnology and Biomedicine (BBZ) Faculty of Chemistry and Mineralogy Leipzig University Leipzig Germany
The selective inhibition of enzymes that catalyze the conversion of arachidonic acid to inflammatory eicosanoids represents a promising approach for cancer therapy. This study, therefore, focuses on the incorporation of metabolically stable, sterically demanding, and hydrophobic carboranes into existing dual cycloxygenase‐2 (COX‐2)/5‐lipoxygenase (5‐LO) inhibitors that are key enzymes in the biosynthesis of eicosanoids. Here, the first carborane‐containing dual COX‐2/5‐LO inhibitors derived from RWJ‐63556 are presented. The replacement of the fluorophenyl moiety by meta‐ or para‐carborane resulted in five carborane‐containing derivatives 3, 6, 9, 13, and 17 that show high inhibitory activities toward COX‐2 and 5‐LO in vitro. Cell viability studies on the A375 melanoma cell line revealed that meta‐carborane derivative 3 shows higher anticancer activity compared to RWJ‐63556 based on accumulation of lipid droplets in the cells due to blockage of the COX‐2 and 5‐LO pathways, indicating a promising approach for the design of potent dual COX‐2/5‐LO inhibitors.
The cylcooxygenase isoforms COX‐1 and COX‐2 are involved in the production of prostaglandins in physiological and pathological processes. The overexpression of COX‐2 under inflammatory conditions, its role in cancer and neurodegenerative diseases necessitates the need to develop and improve nonsteroidal anti‐inflammatory drugs. These mainly unselective COX inhibitors, e.g. aspirin, are used to reduce the symptoms of inflammation. To reduce unwanted side effects connected with unselective inhibition, the development of novel COX‐2 selective inhibitors is a major goal. Herein, the synthesis, characterization and in vitro biological evaluation of eight flurbiprofen‐ and celecoxib‐based carborane analogs are described. Carboranes as hydrophobic surrogates are suitable substituents that can contribute to a selectivity increase toward COX‐2 due to size exclusion. The inhibitory efficacy for COX‐1 and COX‐2 of the four ortho‐ and four nido‐carborane derivatives has been tested. The nido compounds are much more potent than their closo‐carborane analogs. The celecoxib‐based nido‐carborane compound 10 shows an IC50(COX‐2) value in the sub‐μM range and slight selectivity for COX‐2. This is in contrast to its ortho‐carborane counterpart 9, which shows an inhibition preference for COX‐1. While none of these carborane derivatives outperforms their organic analogs, the flurbiprofen‐based nido‐carborane derivatives 14a and 14b surpass the known carborane‐based flurbiprofen analogs.
The presence of inflammatory mediators in the tumor microenvironment, such as cytokines, growth factors or eicosanoids, indicate cancer‐related inflammatory processes. Targeting these inflammatory mediators and related signal pathways may offer a rational strategy for the treatment of cancer. This study focuses on the incorporation of metabolically stable, sterically demanding, and hydrophobic dicarba‐closo‐dodecaboranes (carboranes) into dual cyclooxygenase‐2 (COX‐2)/5‐lipoxygenase (5‐LO) inhibitors that are key enzymes in the biosynthesis of eicosanoids. The di‐tert‐butylphenol derivative tebufelone represents a selective dual COX‐2/5‐LO inhibitor. The incorporation of meta‐ or para‐carborane into the tebufelone scaffold resulted in eight carborane‐based tebufelone analogs that show no COX inhibition but 5‐LO inhibitory activity in vitro. Cell viability studies on HT29 colon adenocarcinoma cells revealed that the observed antiproliferative effect of the para‐carborane analogs of tebufelone is enhanced by structural modifications that include chain elongation in combination with introduction of a methylene spacer resulting in higher anticancer activity compared to tebufelone. Hence, this strategy proved to be a promising approach to design potent 5‐LO inhibitors with potential application as cytostatic agents.
Cyclooxygenase‐2 (COX‐2) and 5‐lipoxygenase (5‐LO) are key enzymes in prostanoid and leukotriene signaling and are overexpressed in various cancers, correlating with malignancy and metastasis. This renders them promising molecular targets for radiotracer development. In this study, isomeric closo ‐dicarbadodecaborane(12)‐based dual COX‐2/5‐LO inhibitors ( 1 and 2 ) served as scaffolds for iodine‐123‐labeling. Iodinated derivatives 3 and 4 inhibited 5‐LO more potently than COX‐2 in vitro ( IC50 0.62 µM and 41.3 µM ( 3 ); 0.54 µM and 67.7 µM ( 4 )). Radioiodination yielded 39%–71% of [123I]3 and [123I]4 ; and the formulations were stabilized with antioxidants. Cellular uptake of [123I]3 and [123I]4 was evaluated in human cells with distinct COX‐2 and 5‐LO expression: U87 glioblastoma, HT‐29 colorectal carcinoma cells, THP‐1 monocytes (MC) and macrophages. Consistent with the observed inhibitory potency, the uptake of the radiotracers proved to be independent of COX‐2 expression. In contrast, it was influenced by 5‐LO expression in tumor but not inflammatory cells. Single‐photon emission computed tomography imaging in tumor xenograft mouse models revealed no tumor retention of [123I]3 and [123I]4 due to rapid metabolism via radiodeiodination. Despite successful radiosynthesis and in vitro evaluation of iodine‐123‐labeled COX‐2/5‐LO inhibitors, improved inhibitory activity and stability are required for development of suitable radiotracers.